CymaBay Therapeutics, Inc.
CBAY · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $2,508,545 | $550,531 | $240,167 | $395,447 |
| - Cash | $206,535 | $20,291 | $125,806 | $28,193 |
| + Debt | $114,494 | $90,921 | $51,582 | $1,744 |
| Enterprise Value | $2,416,504 | $621,161 | $165,943 | $368,998 |
| Revenue | $31,073 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $30,392 | -$710 | -$688 | -$632 |
| % Margin | 97.8% | – | – | – |
| EBITDA | -$85,744 | -$92,401 | -$86,727 | -$50,354 |
| % Margin | -275.9% | – | – | – |
| Net Income | -$105,370 | -$118,891 | -$92,581 | -$48,665 |
| % Margin | -339.1% | – | – | – |
| EPS Diluted | -0.99 | -1.35 | -1.3 | -0.71 |
| % Growth | 26.7% | -3.8% | -83.1% | – |
| Operating Cash Flow | -$72,531 | -$84,080 | -$69,431 | -$44,725 |
| Capital Expenditures | -$445 | -$148 | -$87 | -$21 |
| Free Cash Flow | -$72,976 | -$84,228 | -$69,518 | -$44,746 |